ProCE Banner Activity

Conversas sobre o câncer: o cenário terapêutico em expansão para inibidores de CDK4/6 em câncer de mama HR-positivo/HER2-negativo

PDF

Read these slide notes translated in Brazilian Portuguese to follow along with the associated downloadable slideset providing an overview of CDK4/6 inhibitors in HR+/HER2- breast cancer from early stage through metastatic disease.

Released: August 19, 2024

Expiration: August 18, 2025

Share

Faculty

Sara A. Hurvitz

Sara A. Hurvitz, MD, FACP

Professor of Medicine
Head, Division of Hematology and Oncology
Department of Medicine, UW Medicine
Senior Vice President
Clinical Research Division
Fred Hutchinson Cancer Center
Seattle, Washington

Erica L. Mayer

Erica L. Mayer, MD, MPH

Director of Breast Cancer Clinical Research
Institute Physician
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Joyce O'Shaughnessy

Joyce O'Shaughnessy, MD

Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Chair, Breast Disease Committee
Sarah Cannon Research Institute
Texas Oncology
Dallas, Texas

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Lilly and Novartis Pharmaceuticals Corporation.

Lilly

Novartis Pharmaceuticals Corporation